Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/42181
Full metadata record
DC FieldValueLanguage
dc.creatorDai, Lianpan-
dc.creatorZheng, Tianyi-
dc.creatorXu, Kun-
dc.creatorHan, Yuxuan-
dc.creatorXu, Lili-
dc.creatorHuang, Enqi-
dc.creatorAn, Yaling-
dc.creatorCheng, Yingjie-
dc.creatorLi, Shihua-
dc.creatorLiu, Mei-
dc.creatorYang, Mi-
dc.creatorLi, Yan-
dc.creatorCheng, Huijun-
dc.creatorYuan, Yuan-
dc.creatorZhang, Wei-
dc.creatorKe, Changwen-
dc.creatorWong, Gary-
dc.creatorQi, Jianxun-
dc.creatorQin, Chuan-
dc.creatorYan, Jinghua-
dc.creatorGao, George F.-
dc.date.accessioned2020-08-03T14:10:50Z-
dc.date.available2020-08-03T14:10:50Z-
dc.date.issued2020-
dc.identifier.citationDAI, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell, [S.l.], 2020. No prelo.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0092867420308126pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/42181-
dc.description.abstractVaccines are urgently needed to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for NAbs. Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) which retained the vaccine potency. We generalized this strategy to design vaccines against COVID-19 and SARS, achieving 10- to 100-fold enhancement of NAb titers. RBD-sc-dimers in pilot scale production yielded high yields, supporting their scalability for further clinical development. The framework of immunogen design can be universally applied to other beta-CoV vaccines to counter emerging threats.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceCellpt_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectMiddle East respiratory syndrome CoV (MERS-CoV)pt_BR
dc.subjectCoronaviruspt_BR
dc.subjectBetacoronaviruspt_BR
dc.subjectVaccinept_BR
dc.subjectReceptor-binding domain (RBD)pt_BR
dc.titleA universal design of betacoronavirus vaccines against COVID-19, MERS, and SARSpt_BR
dc.typeArtigopt_BR
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.